Efficacy of an infant formula manufactured from a specific protein hydrolysate derived from whey protein isolate and concentrate produced by Société des Produits Nestlé S.A. in reducing the risk of developing atopic dermatitis

The European Commission asked EFSA to evaluate the efficacy of an infant formula, containing a specific protein hydrolysate derived from whey protein isolate and concentrate and manufactured by Société des Produits Nestlé S.A., in reducing the risk of developing atopic dermatitis in infants with a f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:EFSA J
Autori principali: Castenmiller, Jacqueline, Hirsch‐Ernst, Karen‐Ildico, Kearney, John, Knutsen, Helle Katrine, Maciuk, Alexandre, Mangelsdorf, Inge, McArdle, Harry J, Naska, Androniki, Pelaez, Carmen, Pentieva, Kristina, Siani, Alfonso, Thies, Frank, Tsabouri, Sophia, Turck, Dominique, Vinceti, Marco, Marchelli, Rosangela, van Loveren, Henk, Dumas, Céline, Titz, Ariane, de Henauw, Stefaan
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2021
Soggetti:
Scientific Opinion
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8207397/
https://ncbi.nlm.nih.gov/pubmed/34140987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2903/j.efsa.2021.6603
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi